Endocyte to Present at the Jefferies 2017 London Healthcare Conference
November 09 2017 - 4:01PM
Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company
developing targeted therapeutics for personalized cancer treatment,
today announced that the company’s management team will present at
the Jefferies 2017 London Healthcare Conference on Wednesday, Nov.
15, 2017, at 8:40 a.m. GMT.
A live audio webcast of the Company’s presentation
can be accessed by visiting “Events & Presentations” under the
Investors & News section of Endocyte’s website at
www.endocyte.com. The webcast will be archived shortly after the
live event, and a replay will be available on the Company’s website
for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the treatment of cancer. Endocyte uses drug
conjugation technology to create novel therapeutics and companion
imaging agents for personalized targeted therapies. The company’s
agents actively target receptors that are over-expressed on
diseased cells relative to healthy cells, such as prostate-specific
membrane antigen (PSMA) in prostate cancer. This targeted approach
is designed to safely enable the delivery of highly potent drug
payloads. The companion imaging agents are designed to identify
patients whose disease over-expresses the target of the therapy and
who are therefore more likely to benefit from treatment. For
additional information, please visit Endocyte’s website at
www.endocyte.com.
Contacts:Stephanie Ascher, Stern Investor
Relations, Inc., (212) 362-1200, stephanie@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Sep 2023 to Sep 2024